Latest Market Data
Refresh
Market Turnover
-






-
-
|
|
|
|
|
|
-
-
-
Loading

IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC. - B - H SHARES (1541)

IMMUNEONCO-B (1541)

HK$10.480

-0.080 (-0.76%)

Prev. Close is the most recent non-zero closing value or settlement price.PREV. CLOSE
HK$10.560
Open price is the first traded price of the day. The opening price is reported after 09:20:00 HKT.OPEN
HK$10.560
TURNOVER
HK$13.67M
VOLUME
1.31M
MKT CAP
HK$4.15B
LOT SIZE
200
BID
HK$10.400
ASK
HK$10.480
EPS
-
P/E
-
DIV YIELD
-
INTRA-DAY 52W
High HK$10.700 HK$22.000
Low HK$10.300 HK$3.210
Information is available after the market opens and is delayed by at least 15 minutes.
Updated: 25 Jul 2025 16:08 HKT
  • 1 D
  • 1 M
  • 3 M
  • 6 M
  • YTD
  • 1 Y
  • 2 Y
  • 5 Y
  • 10 Y
1min
5min
15min
Hourly
Created with Highstock 6.2.00.00010.08010.32010.56010.80011.040080K160K10:0011:0012:0013:0014:0015:0016:00Prev. Close
10.560
All charts use the last traded price or closing price.

COMPANY PROFILE

ImmuneOnco Biopharmaceuticals Shanghai Inc is a China-based company mainly engaged in the development of tumor immunotherapy. The Company's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The Company mainly operates its businesses in the domestic and overseas markets. *
Please click to see notes of Issued Shares.Issued Shares (excluding treasury shares) 396,277,305 (as at 30 Jun 2025)
Industry Healthcare - Pharmaceuticals & Biotechnology - Biotechnology Industry Classification (HSIC) is provided by Hang Seng Indexes Company Limited. Please see the . (HSIC)
Listing Date 5 Sep 2023
Financial Year Ends 31 Dec 2024
Chairman Tian Wenzhi
Principal Office Unit 15, 1000 Zhangheng Road
China(SH)Pilot Free Trade Zone
Pudong New Area
Shanghai, PRC
Place of Incorporation PRC
Listing Category Primary Listing

a. Updating time-lag
The number of issued shares / issued units presented is generally updated within 7 days after the Monthly Returns and Next Day Disclosure Returns published by the listed issuers on the HKEXnews website. Hence, the information presented here may not be the most up-to-date information submitted by the listed issuers as required under the Listing Rules.
b. Rights issues or bonus issues
The number of issued shares / issued units presented here will be adjusted with effect from the ex-date in the event of announced rights issues or announced bonus issues. In this case, both the number of issued shares / issued units before and after the adjustment will be presented.
c. Share splits or share consolidations
The number of issued shares / issued units presented here will be adjusted on the effective date in the event of share splits or share consolidations.
d. Conversion of convertible notes into shares
If the change of the number of issued shares / issued units is due to conversion of convertible bonds, the number of issued shares / issued units presented here may be updated based on the related company announcement.
Updated: 25 Jul 2025 19:03 HKT
* Company profile is provided by Refinitiv.

ENTITLEMENT

Date Announced Ex-Date Details Financial Year End Book Close Date Payment date may be indicative only.Payment Date
25 Mar 2025-No Dividend for the period ended
2024/12/31
31 Dec 2024--
26 Aug 2024-No Dividend for the period ended
2024/06/30
31 Dec 2024--
25 Mar 2024-No Dividend for the period ended
2023/12/31
31 Dec 2023--
Updated: 25 Jul 2025 01:15 HKT
Dividend details are sourced from Announcement Forms published on HKEXnews